Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Celecoxib Oral Solution Treats Migraine in Randomized Trial

Publish date:: January 29, 2020

Key clinical point: An oral liquid solution of celecoxib, known as DFN-15, is more effective than placebo for the acute treatment of migraine.

Major finding: At 2 hours, pain freedom rates were 35.6% with celecoxib oral solution and 21.7% with placebo. The rates of freedom from the most bothersome symptom were 57.8% with celecoxib oral solution and 44.8% with placebo.

Study details: A randomized, double-blind, placebo-controlled study that included about 600 patients with episodic migraine with or without aura.

Disclosures: The trial was supported by Dr. Reddy’s Laboratories, manufacturer of DFN-15. Two authors are employed by and own stock in Dr. Reddy’s. Other authors disclosed research support from and consulting for Dr. Reddy’s and other companies.

Citation:

Lipton RB et al. Headache. 2020;60(1):58-70. doi: 10.1111/head.13663.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Neurology

HIT-6 may help track meaningful change in chronic migraine,

Vascular dementia risk particularly high in type 2 diabetes,

Blood biomarkers could help predict when athletes recover from concussions,

Mortality burden of dementia may be greater than estimated,

Multiple traits more common in difficult-to-treat patients with migraine,